India Plasma Fractionation Market Size, Share & COVID-19 Impact Analysis, By Product (Albumin, Immunoglobulin, Coagulation Factors (Factor VIII, Factor IX, and Others), and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others), By End-user (Hospitals & Clinics, Research Organizations, and Others), and Forecast, 2021-2030

The India plasma fractionation market was valued at USD 331.7 million in 2020. The market is projected to grow from USD 326.3 million in 2021 to USD 470.6 million by 2030, exhibiting a CAGR of 4.2% during the 2021-2030 period. The global impact of COVID-19 has been unprecedented and staggering, with plasma fractionation witnessing a positive impact on demand across all regions amid the pandemic. Based on our analysis, the India market exhibited an average growth of 3.6% in 2020 as compared to the average year-on-year growth during 2017-2019. The rise in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over. 

Blood consists of ~55% plasma, ~44% red blood cells, and <1% white blood cells and platelets. Blood plasma contains a wide variety of proteins such as immunoglobulins, albumin, and clotting factors. The downstream process used for the separation of plasma into its constituent proteins is known as plasma fractionation. Plasma can be obtained through whole blood as well as apheresis. However, commercial apheresis is not allowed in India. The collection of source plasma could be encouraged only as a voluntary activity in India. Plasma proteins can be used as therapies for people suffering from shock, burns, trauma, immune-deficiency disorders, and other medical conditions.

The market growth is attributed to the increasing number of patients suffering from shock, burns, and trauma. Moreover, a large patient pool affected by immune-deficiency disorders drives the market growth. Furthermore, rising focus of market players to increase their production capacities and the growing adoption of clotting factors to treat various types of hemophilia, such as Hemophilia A and Hemophilia B, boost the market.

• For instance, according to the recent data by the India Fit Report 2020, 20.8% of the people in India have low immunity levels. Such low immunity levels can lead to serious immune-deficiency disorders, which is expected to increase the demand for plasma proteins.

COVID-19 IMPACT

COVID-19 Pandemic Boosted Market Revenue Due to Increased Adoption of Immunoglobulins

The COVID-19 pandemic positively impacted the market in 2020. Factors such as the surging number of patients suffering from COVID-19 and increasing adoption of antibodies in 2020, contributed positively to the market growth. The India plasma fractionation market growth witnessed a rate of 3.6% in 2020 as compared to 2.6% in 2019.

• For instance, as per the Fourth National Serosurvey conducted by the Indian Council of Medical Research (ICMR) for COVID-19, in July 2021, approximately 68% of the population in India have antibodies against COVID-19.

Additionally, in 2020, market players have focused on various strategies to meet the growing demand for antibodies. Several companies launched new products in the market to address the problem of the COVID-19 pandemic.

• In August 2020, Intas Pharmaceuticals Ltd., through its research & development team, developed a COVID-19 specific Hyperimmune Globulin for the treatment of patients suffering from moderate to severe COVID-19 infection. This new product had been an important therapeutic option to help combat the COVID-19 until a vaccine was available in India. 

With the increase in demand for plasma-derived medicinal products, the market players have also increased their production capacities to fulfill the demand, resulting in high revenue compared to the historic years.

• For instance, Intas Pharmaceuticals Ltd. registered a revenue of USD 2,447.7 million in 2020, with the Y-o-Y growth of 12.0% from USD 2,185.4 million in 2019 due to the high demand for immunoglobulin products in the country.

LATEST TRENDS

Strategic Initiatives to Boost Market Growth

The companies operating in the market constantly focus on strategies such as acquisitions, expansions, and mergers. These strategies help the companies increase their revenue, thereby fostering the overall market growth opportunities.

• For instance, in August 2021, Reliance Life Sciences announced to invest USD 282.0 million in Maharashtra Industrial Development Corporation. The company will work on the research and manufacturing of plasma proteins and other products.  

Moreover, many market players are involved in developing new plasma proteins for the treatment of various immune-deficiency disorders, which is expected to drive market growth in the coming years. 

DRIVING FACTORS

Rising Prevalence of Immune-deficiency Disorders to Drive Market Growth

Immune-deficiency disorders are a group of diseases that affect various arms of the immune system. X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), selective IgA deficiency with or without IgG2 subclass deficiency, isolated IgG2 subclass deficiency, and transient hypogammaglobulinemia of infancy are some of the most common immune-deficiency disorders in India.

• According to the Plasma Protein Therapeutic Association (PPTA), Intravenous Immunoglobulin (IVIG) is the only effective treatment for primary immunodeficiency disease. Also, it has been proven clinically beneficial in the treatment of secondary immune deficiency diseases and other neurological disorders.

The increasing number of people suffering from immune-deficiency disorders in India is expected to increase the adoption of plasma proteins thereby, fostering the overall market growth.

• For instance, according to the recently published statistics by the Foundation for Primary Immunodeficiency Diseases (FPID), more than 1 million adults and children in India have a primary immunodeficiency. Such a large patient pool is expected to increase the adoption of plasma proteins in the coming years, thereby spurring the overall market growth.

Increasing Demand for Coagulation Factors Due to High Burden of Hemophilia Strengthens Market Growth

Coagulation factors are the proteins in the plasma that help in the treatment of bleeding disorders. The extent of the clotting factor in the person’s blood decides the severity of hemophilia. The large number of patients suffering from hemophilia is expected to increase the demand for coagulation factors in the coming years. 

• For instance, according to the recently published data by the World Federation of Hemophilia, in 2020, the number of patients with hemophilia A was 18,928. Moreover, the number of patients suffering from hemophilia B stood at 3,104 in 2020.

With the rising number of hemophilia cases, the demand for coagulation factors is expected to increase during the forecast period. In India, the consumption of coagulation factors has increased over the past few years.

• According to the Annual Global Surveys conducted by the World Federation of Hemophilia, in 2018, the total consumption of factor VIII in India was 311,722,250 IU (International Units), which has increased by 26.8% to reach 395,397,750 IU in the year 2019. 

Thus, the rising coagulation factor VIII consumption and the growing prevalence of hemophilia A drive the market growth.

RESTRAINING FACTORS

Low Availability of Domestic Plasma to Limit the Market Growth

With a high burden of chronic diseases in India, the shortage of blood and plasma creates a disturbance. The main factor contributing to India's blood shortage is deterioration during storage and expiry. Moreover, issues, such as contamination under donations, broken bags or seals, clotted donations, delays in conducting tests due to improper transport, and staff shortage, increase blood & plasma shortage and decrease the plasma available for fractionation.

• According to the recent news article published by Printline Media Pvt. Ltd. in June 2020, India wastes approximately 6.5 lakh units of blood and blood components on an annual basis.

The plasma for fractionation is very low due to such high blood wastage. Moreover, the increasing use of plasma for clinical applications reduces the amount of plasma available for fractionation.

• According to the recent statistics published by the Ministry of Health and Family Welfare, in 2018-2019, the total collection of blood in India was 12.2 million units, out of which 75.05% of blood was componentized in National AIDS Control Organization (NACO) supported blood component separating units (BCSU). Thus, the wastage of 24.95% of blood hampered the market growth across the country.

SEGMENTATION

By Product Analysis

Immunoglobulin Segment to Hold a Major Share of the India Market During 2021-2030

Based on product, the India plasma fractionation market is segmented into albumin, immunoglobulin, coagulation factors, and others. 

The immunoglobulins segment held the highest market share in 2020 and is anticipated to expand at the fastest CAGR during the forecast period. The large share of the immunoglobulins segment is attributed to the increasing incidence of autoimmune, idiopathic, and infectious disorders and the rising focus of market players to launch immunoglobulins in the coming years. 

• For instance, according to the data by the National Health Portal of India, around 75% of the people suffering from autoimmune disorders are women. Such a high prevalence of autoimmune diseases among women is expected to increase the adoption of immunoglobulins in the coming years.

The albumin segment is projected to expand at a substantial CAGR during the forecast period. Factors, such as increasing number of surgical procedures, rising prevalence of burns, and increasing use of albumin for the treatment of shock and other severe infections, are expected to contribute to the segmental growth.

By Application Analysis

Immunology & Neurology Segment to Dominate the Market During the Forecast Period

Based on application, the market is segmented into immunology & neurology, hematology, critical care, pulmonology, and others. 

The immunology & neurology segment accounted for the largest market share in 2020 and is expected to expand at a significant CAGR during the forecast period. The growing prevalence of primary immunodeficiency disorders and the rising demand for immunoglobulins for various medical conditions drive the segmental growth.

• For instance, according to data from a research article published by National Center for Biotechnology Information (NCBI), in 2017, the estimated number of patients with primary immunodeficiency (PID) in India was more than one million. Such PID-affected population requiring immunoglobulins is expected to boost the segment during the forecast timeframe.       

The hematology segment is anticipated to expand at a substantial CAGR during the forecast period, 2021-2030. The segmental growth is attributed to the increasing number of patients suffering from bleeding disorders and rising use of Coagulation Factor VIII and Factor IX in India.

• According to the annual global survey by the World Federation of Hemophilia, in 2020, the number of patients suffering from Hemophilia B in India was 3,104, up from 14.3% compared to 2018. Such a growing patient population requiring factor IX is anticipated to contribute to the segmental growth in future. 

By End-user Analysis

Hospitals & Clinics Segment to Continue Dominance During the Forecast Period

Based on end-user, the market is segmented into hospitals & clinics, research organizations, and others.

In 2020, the hospitals & clinics segment held the highest market share and is expected to expand at the highest CAGR during the forecast timeframe, 2021-2030. This segment's large share and high growth rate are attributed to the increasing number of surgical procedures in hospitals, high flow of patients suffering from immune-deficiency disorders in hospitals & clinics, growing use of albumin in hospitals for burns, and rising number of hospitals & clinics in India. 

• For instance, according to the recently published news article by the Hindu in January 2021, India has around 70 lakh burn injuries annually, with the highest death rate of 1.4 lakh per year. Moreover, an additional 2.4 lakh patients among these burn injuries end up with severe deformities. Such an increased incidence of burns in India is expected to increase the patient footfall in hospitals & clinics thereby, spurring segmental growth.

KEY INDUSTRY PLAYERS

Companies with the Fractionation Plants/Centers to Hold Key Market Share

The India market is highly consolidated due to the presence of limited players offering plasma proteins in India. Key players, such as Reliance Life Sciences, Intas Pharmaceuticals Ltd, Hemarus, and VIRCHOW BIOTECH, accounted for the majority of the market share in 2020.

Reliance Life Sciences dominated the market in 2020. The company has the oldest in-house plasma fractionation unit, which is one of the key factors contributing to its dominance in India. Moreover, factors, such as better capabilities in research & development, manufacturing, process development, and marketing, strengthen its market share in India.

Other companies, such as PlasmaGen BioSciences Pvt. Ltd., Bharat Serums and Vaccines Limited (BSV), Biocon Limited, and Fusion Healthcare, held substantial market shares due to their strong presence in India. Furthermore, strategic initiatives such as production capacity expansion and new product launches are expected to increase their market shares in the long run.

LIST OF KEY COMPANIES PROFILED:

• PlasmaGen BioSciences Pvt. Ltd. (Bangalore, India)


• Reliance Life Sciences (Mumbai, India)


• Biocon Limited (Bangalore, India)


• Intas Pharmaceuticals Ltd. (Ahmedabad, India)


• Bharat Serums and Vaccines Limited (BSV) (Mumbai, India)


• VIRCHOW BIOTECH (Hyderabad, India)


• Fusion Healthcare (Hyderabad, India)


• Kedrion S.p.A (Barga, Italy)


• Hemarus (Hyderabad, India)

KEY INDUSTRY DEVELOPMENTS:

• May 2019 –Reliance Life Sciences imported plasma from Taiwan to control the albumin shortage in Maharashtra. 


• August 2017 – PlasmaGen BioSciences Pvt. Ltd. announced to create a manufacturing facility in Karnataka, India and also aims to reach a turnover of USD 100-120 million in the next five years.

REPORT COVERAGE

The India plasma fractionation market research report provides a detailed analysis of the industry. It focuses on key aspects such as leading companies, types of plasma proteins, and product applications. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the factors mentioned above, the report includes insights related to plasma fractionation regulations, production capacity, future strategies of the market players, investment initiatives, self-sufficiency of plasma-derived medicinal products (PDMPs), and supply chain analysis. 

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2017-2030
Base Year	2020
Estimated Year	2021
Forecast Period	2021-2030
Historical Period	2017-2019
Unit	Value (USD Million)
Segmentation	By Product Albumin Immunoglobulins Coagulation Factors Factor VIII Factor IX Others Others
By Application Immunology & Neurology Hematology Critical Care Pulmonology Others
By End-user Hospitals & Clinics Research Organizations Others